A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2019
At a glance
- Drugs FOR-46 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Fortis Therapeutics
- 05 Feb 2019 Planned End Date changed from 20 Dec 2020 to 20 Jun 2020.
- 05 Feb 2019 Planned primary completion date changed from 20 Oct 2020 to 20 Apr 2020.
- 05 Feb 2019 Status changed from not yet recruiting to recruiting.